A Phase II Study of Risk-adapted Donor Lymphocyte Infusion and Azacitidine for the Prevention of Hematologic Malignancy Relapse Following Allogeneic Stem Cell Transplantation

Trial Profile

A Phase II Study of Risk-adapted Donor Lymphocyte Infusion and Azacitidine for the Prevention of Hematologic Malignancy Relapse Following Allogeneic Stem Cell Transplantation

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 May 2017

At a glance

  • Drugs Azacitidine (Primary) ; Azacitidine (Primary)
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Juvenile myelomonocytic leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 23 May 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2019.
    • 23 May 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Mar 2019.
    • 23 May 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top